Mark Draluck

Mark Draluck serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of critical biomedical and diagnostic capabilities. He manages a diverse portfolio of contracts focused on laboratory diagnostics, pharmaceutical preparation, and data-driven public health systems, ensuring timely access to technologies that enable disease surveillance, outbreak response, and clinical research. His work directly supports CDC’s operational readiness by facilitating the procurement of high-integrity scientific equipment, in-vitro diagnostic substances, and computational systems essential for real-time epidemiological analysis. Draluck maintains sustained partnerships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid, reflecting a preference for established industry players with proven expertise in life sciences and public health infrastructure. His contracting patterns emphasize performance-based outcomes, technical compliance, and supply chain reliability, particularly for products requiring FDA-regulated manufacturing standards or CLIA-certified laboratory integration. These relationships are characterized by long-term strategic alignment rather than transactional procurement, ensuring continuity in mission-critical deployments. His set-aside preferences are heavily skewed toward open competition, with 94.1% of awards issued without socioeconomic set-asides, indicating a primary focus on technical merit and mission necessity over socioeconomic criteria. While 8(a) competed awards represent 5.9% of his portfolio, this reflects targeted, limited use of small business authorities only when aligned with specialized capability gaps, demonstrating a balanced but mission-driven approach to socioeconomic contracting. Draluck’s procurement focus centers on NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325413 (In-Vitro Diagnostic Substance Manufacturing), each accounting for 23.5% of activity, underscoring deep expertise in regulated biopharmaceutical and diagnostic product acquisition. He also regularly procures computer systems design services under NAICS 541512 to support data analytics platforms and public health information systems, reflecting his technical fluency in integrating laboratory diagnostics with digital health infrastructure.